top of page

Pavaka Wound Care Joins Rev1 Ventures' Fall 2025 Customer to Capital Accelerator

Writer: Brent Toto
Brent Toto
Aug 18, 2025
2 min read

Updated: 7 days ago

COLUMBUS, Ohio — August 18, 2025 — Rev1 Ventures has named Pavaka Wound Care one of seven startups in its Fall 2025 Customer to Capital accelerator. The 14-week program is for founders who have validated their market and are ready to win early customers and become investment-ready.


Rev1 Ventures Fall 2025 Customer to Capital cohort at kickoff

Rev1 announced the cohort in a blog post titled "Seven Startups Taking on Problems Once Thought Unsolvable." Pavaka joins AISIRI Financial, CygnusMed, Infuse Retrievable Stentgraft, Red Sparrow, Securely Group and Tactical Triage Technologies. The companies span healthcare, finance and training, and three of them are developing medical technologies.


Pavaka earned its place after completing Rev1's Concept to Customer program in July 2025, where its pitch was voted the participants' favorite by peers and mentors.


Over the next 14 weeks, Rev1 will work with Pavaka's founders, CEO Brent Toto and CTO Frank Fischer, on four areas: securing first customers, strengthening the company's competitive edge, building financial and capital models, and preparing and polishing an investor pitch. Rev1 introduced the cohort to the Columbus innovation community at a Meet the Companies event on August 20.


Pavaka is developing an investigational electroceutical wound dressing, built on technology exclusively licensed from The Ohio State University. The dressing generates a low-level electric field at the wound surface. It is being developed for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms, for both civilian health systems and military medicine.


For a medical device company, the accelerator's focus on customers and capital comes at the right time. Pavaka is working through regulatory strategy, design for manufacturing with its Ohio manufacturing partner, and conversations with clinicians and strategic partners. Each of those workstreams benefits from Rev1's mentors and network.


Pavaka joins the program as a company already backed by an exclusive Ohio State license and a Technology Validation and Start-up Fund award from the Ohio Department of Development, announced in April 2025.


"Rev1 has helped build some of Ohio's most successful companies, and we're proud to be part of this cohort. Customer to Capital is the right program at the right moment for Pavaka." — Brent Toto, CEO and Co-Founder

Investigational device: Pavaka's electroceutical wound dressing has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.


About Pavaka Wound Care: Pavaka Wound Care is a Columbus, Ohio–based medical device company developing an electroceutical advanced wound dressing for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms. Built on technology exclusively licensed from The Ohio State University, the investigational dressing generates a low-level electric field at the wound surface. Pavaka was co-founded by CEO Brent Toto and CTO Frank Fischer. Learn more at www.pavakawoundcare.com.


Sources and further reading

Comments


bottom of page